Barinthus Biotherapeutics (BRNS) Net Equity Issued and Repurchased (2021 - 2024)
Barinthus Biotherapeutics' (BRNS) quarterly Net Equity Issued and Repurchased came in at $837000.0 in Q4 2024, up 667.89% YoY from $109000.0 in Q1 2024, and up 80.0% on a QoQ basis from $465000.0 in Q3 2024.
Barinthus Biotherapeutics (BRNS) Net Equity Issued and Repurchased (2021 - 2024) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $837000.0 in Q4 2024.
- Quarterly Net Equity Issued and Repurchased rose 667.89% year-over-year to $837000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $837000.0 (down 41.67% YoY) and the FY2024 annual result came in at $2.2 million, up 6.29% from the prior year.
- Net Equity Issued and Repurchased advanced to $837000.0 in Q4 2024, from $465000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $125.2 million in Q2 2021 to a low of $46000.0 in Q3 2023.
- A 3-year average of $14.4 million and a median of $465000.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 910.87% in 2024, down 71.88% in 2024.
- Tracing BRNS's Net Equity Issued and Repurchased over 3 years: stood at $125.2 million in 2021, then tumbled by 99.91% to $109000.0 in 2023, then surged by 667.89% to $837000.0 in 2024.
- The last three Net Equity Issued and Repurchased figures came in at $837000.0 (Q4 2024), $465000.0 (Q3 2024), and $358000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 837,000.00 |
| Dec 31, 2024 | 837,000.00 |
| Sep 30, 2024 | 465,000.00 |
| Sep 30, 2024 | 465,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Mar 31, 2024 | 503,000.00 |
| Dec 31, 2023 | 109,000.00 |
| Dec 31, 2023 | 109,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Mar 31, 2023 | 1.79 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Jun 30, 2021 | 125.24 Mn |
| Jun 30, 2021 | 125.24 Mn |